The Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation

Table 5

An analysis of the associations between two genetic factors and risk of aGvHD using the Svejgaard and Ryder method [19].

(a) Factor A (carriers of A alleles for CD86 rs1129055 in recipients) and factor B (possessing the CT60GG (rs3087243 GG) genotype for the CTLA-4 gene in recipients)

	aGvHD present		aGvHD absent
A+B+	35		13
A−B+	32		25
A+B−	29		36
A−B−	39		51
Test	OR		95% CI	Comparison	Individual association
(1) A	1.58	0.07	0.97–2.58
(2) B	2.25	0.002	1.35–3.75
(3) ++ versus −+	2.10	0.08	0.92–4.80	A in B-positive	A association
(4) +− versus −−	1.05	0.87	0.55–2.00	A in B-negative
(5) ++ versus +−	3.34	0.003	1.49–7.46	B in A-positive	B association
(6) −+ versus −−	1.67	0.13	0.86–3.27	B in A-negative
(7) +− versus −+	0.63	0.21	0.31–1.29	Differences between A and B association
(8) ++ versus −−	3.52	0.001	1.65–7.35	Combined association

(b) Factor A (carriers for the CD86 rs1129055GG genotype in donors) and factor B (possessing the CT60GG (rs3087243GG) genotype for the CTLA-4 gene in recipients)

	aGvHD present		aGvHD absent
A+B+	36		14
A+B−	32		41
A−B+	26		21
A−B−	33		35
Test	OR		95% CI	Comparison	Individual association
(1) A	1.l7	0.54	0.70–1.95
(2) B	2.07	0.007	1.22–3.52
(3) ++ versus −+	2.08	0.09	0.89–4.83	A in B-positive	A association
(4) +− versus −−	0.83	0.58	0.43–1.61	A in B-negative
(5) ++ versus +−	3.29	0.002	1.52–7.12	B in A-positive	B association
(6) −+ versus −−	1.31	0.47	0.62–2.77	B in A-negative
(7) +− versus −+	0.63	0.22	0.30–1.32	Differences between A and B association
(8) ++ versus −−	2.73	0.02	1.25–5.95	Combined association